Literature DB >> 16940942

Mouse models of neointimal hyperplasia: techniques and applications.

Xinwen Wang1, Hong Chai, Peter H Lin, Alan B Lumsden, Qizhi Yao, Changyi Chen.   

Abstract

Neointimal hyperplasia is a major cause of the failure in vascular reconstructive procedures such as angioplasty, vascular stenting, small caliber vascular graft, and vein graft. However, the underlying molecular mechanisms are not yet fully understood. The study of neointimal hyperplasia has relied heavily on the use of experimental animal models. Recent development in gene manipulation techniques in mice offers a unique opportunity to unravel the molecular basis of the neointimal response at the genetic level, which is critical to develop new strategies to prevent human neointimal hyperplasia. Several mouse models for studying neointimal hyperplasia have recently been established including blood-flow cessation, mechanical injury, and vein bypass graft. In an attempt to elaborate these models, this review highlights the characteristics, advantages, disadvantages, and applications of these mouse models in vascular disease. In addition, the difference between mouse models and human lesions is discussed. Thus, this review provides updated information and helps vascular surgeons and other vascular biologists in selecting appropriate mouse models for their research on neointimal hyperplasia.

Entities:  

Mesh:

Year:  2006        PMID: 16940942

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  8 in total

1.  Calreticulin Regulates Neointima Formation and Collagen Deposition following Carotid Artery Ligation.

Authors:  Kurt A Zimmerman; Dongqi Xing; Manuel A Pallero; Ailing Lu; Masahito Ikawa; Leland Black; Kenneth L Hoyt; Janusz H Kabarowski; Marek Michalak; Joanne E Murphy-Ullrich
Journal:  J Vasc Res       Date:  2016-02-25       Impact factor: 1.934

2.  Ginkgolide A-gold nanoparticles inhibit vascular smooth muscle proliferation and migration in vitro and reduce neointimal hyperplasia in a mouse model.

Authors:  Sarah M Weakley; Xinwen Wang; Hong Mu; Jianming Lü; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  J Surg Res       Date:  2011-04-01       Impact factor: 2.192

3.  A novel model of accelerated intimal hyperplasia in the pig iliac artery.

Authors:  Rabih Houbballah; Alessandro Robaldo; Hassan Albadawi; James Titus; Glenn M LaMuraglia
Journal:  Int J Exp Pathol       Date:  2011-11-03       Impact factor: 1.925

4.  Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury.

Authors:  Suvi T Ruohonen; Ken Abe; Mia Kero; Laura Toukola; Saku Ruohonen; Matias Röyttä; Markku Koulu; Ullamari Pesonen; Zofia Zukowska; Eriika Savontaus
Journal:  Peptides       Date:  2008-12-24       Impact factor: 3.750

5.  Ubiquitin-specific Protease 20 Regulates the Reciprocal Functions of β-Arrestin2 in Toll-like Receptor 4-promoted Nuclear Factor κB (NFκB) Activation.

Authors:  Pierre-Yves Jean-Charles; Lisheng Zhang; Jiao-Hui Wu; Sang-Oh Han; Leigh Brian; Neil J Freedman; Sudha K Shenoy
Journal:  J Biol Chem       Date:  2016-02-02       Impact factor: 5.157

6.  Neointimal Hyperplasia after Carotid Transection and Anastomosis Surgery is Associated with Degradation of Decorin and Platelet Derived Growth Factor Signaling.

Authors:  Roshan J D'Cruz; Valerie B Sampson; Carly A Askinas; Rebecca A Scott; Karyn G Robinson; Claude A Beaty; Anne M Hesek; Robert E Akins
Journal:  JVS Vasc Sci       Date:  2020-10-21

7.  Preclinical techniques to investigate exercise training in vascular pathophysiology.

Authors:  Gurneet S Sangha; Craig J Goergen; Steven J Prior; Sushant M Ranadive; Alisa M Clyne
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-01-01       Impact factor: 5.125

8.  MARCKS Signaling Differentially Regulates Vascular Smooth Muscle and Endothelial Cell Proliferation through a KIS-, p27kip1- Dependent Mechanism.

Authors:  Dan Yu; George Makkar; Tuo Dong; Dudley K Strickland; Rajabrata Sarkar; Thomas Stacey Monahan
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.